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Introduction: The immunogenicity of BCG vaccination in infants differs between
populations. We hypothesized that prenatal exposure to mycobacterial antigens might
explain the differences in immune responses to BCG seen in other studies of infants in
Africa and the United Kingdom (UK) and we explored this in birth cohorts in Uganda and
the UK.
Materials and Methods: Blood samples were obtained from BCG-immunized infants
of mothers with (n = 110) and without (n = 121) latent Mycobacterium tuberculosis
infection (LTBI) in Uganda and BCG-immunized infants of mothers without LTBI (n = 25)
in the UK at 10 and 52weeks after birth. Cytokine and chemokine responses to PPDwere
measured to assess responses to BCG immunization, and to ESAT6/CFP10 to assess
exposure to or infection with M. tuberculosis or non-tuberculous mycobacteria (NTM) in
6-day whole blood culture supernatants by a 17-plex Luminex assay. Median responses
were compared between Ugandan infants (together, and separated by maternal LTBI
status) and UK infants.
Results: The IFN-γ response to BCG vaccination was similar between Ugandan
and UK infants at 10 and 52 weeks. At week 52, TNF production was marginally
higher in Ugandan infants, but after adjusting for multiple comparisons this difference
was not significant. At weeks 10 and 52, stimulation of blood with ESAT6/CFP10
produced significantly higher IFN-γ, TNF, IL-12p40, IL-1α, IL-1β, IL-1Ra, IP-10, MIP-1α,
MIP-1β, and GM-CSF in Ugandan compared to UK infants. Stimulation of blood with
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ESAT6/CFP10 produced significantly higher amounts of IL-8 (p = 0.0001), IL-10
(p = 0.0022), and IL-13 (p = 0.0020) in the UK than in Ugandan infants of mothers
without LTBI at week 10, but not at week 52.
Conclusions: Immune responses to mycobacterial antigens following BCG
immunization are similar for PPD, but differ for ESAT6/CFP10, between infants in Uganda
and the UK. Neither maternal LTBI nor infant exposure to or infection with mycobacteria
impacts the response to BCG. The observed global differences in immune response to
BCG immunization are likely to be due to other causes.
Keywords: BCG vaccine, cytokine responses, chemokine responses, mycobacterial antigens, latent
Mycobacterium tuberculosis infection
INTRODUCTION
The protective efficacy of Bacille Calmette-Guerin against
tuberculosis (TB) varies geographically, ranging from 0 to 80%
(1–3), with lower protection demonstrated in tropical countries
(4). Factors including exposure to non-tuberculous mycobacteria
(NTM) (3, 4) and other common infections in the tropics (5) may
alter the efficacy of BCG immunization.
BCG immunization of infants induces a measurable immune
response to mycobacterial antigens, such as purified protein
derivative (6) of Mycobacterium tuberculosis, with infants
shown to generate cytokine-expressing T cell responses of
the same magnitude as adults, (7) characteristically with a
T helper (Th) 1 bias (8). Various studies have demonstrated
T-cell responses to mycobacterial antigens following BCG
immunization of infants (9–12). However, studies in Uganda,
Malawi, The Gambia, Indonesia and the UK (9, 11, 13–16)
have shown different patterns of response to BCG immunization
in infants, with Th1 responses predominant among infants
in the UK, contrasting with Th2 responses seen among
infants in Malawi (13). Responses among infants in Malawi
and The Gambia were partially explained by the season of
birth (11, 14).
The profile of immune response to BCG immunization seen
in infants from Malawi may be similar to other settings in sub-
Saharan Africa where the protective efficacy of BCG is low. We
aimed to explore whether prenatal exposure to mycobacterial
antigens explained the Africa-UK differences to any extent using
samples obtained from a study that investigated the impact
of maternal latent M. tuberculosis infection (LTBI) on the
infant response to BCG immunization (17). In murine studies,
mycobacterial antigens have been shown to cross the placenta
following gestational treatment with mycobacterial antigens (18).
Our proposition is therefore that maternal LTBI might lead
to exposure to mycobacterial antigens in utero resulting in
sensitization (19), or tolerance (19, 20) in the unborn babies.
Passive transfer of maternal anti-mycobacterial antibodies or
maternal anti-idiotype antibodies (mimicking antigen) have been
proposed as an alternative mechanism (21). The maternal and
placental immunological environment could also be affected
non-specifically by maternal LTBI, with impact on neonatal and
fetal immune responses (22).
We analyzed and compared responses between infants of
mothers with andwithout LTBI inUganda and infants of mothers
without LTBI in the UK and hypothesized that the responses to
BCG immunization would differ between infants in Uganda and
the UK.We also anticipated that responses in Ugandan infants of
mothers without LTBI would be more similar to responses in UK
infants than responses in Ugandan infants of mothers with LTBI.
MATERIALS AND METHODS
Study Design and Participants
Between June 2014 and October 2016, healthy Ugandan mothers
and their infants were recruited at Entebbe General Hospital as
part of a larger study to investigate the impact of maternal LTBI
on the infant response to BCG immunization (17).
To be included in the study, women had to give consent
to participate, have a normal singleton pregnancy, have an
uncomplicated delivery of a neonate >2,500 g, be residing
in Entebbe municipality or Katabi sub-county, and be HIV
negative. Participants among whom cord blood was not obtained,
delivery was not normal, the mother was unwilling to undergo a
repeat HIV test or found to be HIV-positive on repeat testing,
the mother had indeterminate LTBI status, the neonate was
unwell as judged by the midwife, or the neonate presented
with significant congenital abnormalities likely to impair the
child’s general health and development were excluded. All
vaccines recommended by the Expanded Programme (EPI)
on Immunization were administered to the enrolled Ugandan
infants and these included oral poliovirus vaccine (OPV) at birth,
diphtheria-tetanus toxoids and pertussis (DTP), Haemophilus
influenzae type B (HiB), hepatitis B (HBV) and OPV at 6, 10, and
14 weeks of age, and measles at 9 months of age.
Between March 2015 and August 2017, infants in the UK
were recruited at North Middlesex Hospital, London if their
mothers were willing to participate, had a singleton pregnancy,
had an uncomplicated delivery of a neonate >2,500 g and
were LTBI-negative as determined by the T-SPOT.TB assay
(Oxford Immunotec). Infant vaccines administered in the UK
were the 6-in-1 vaccine (diphtheria, hepatitis B, HiB, polio,
tetanus, pertussis, rotavirus vaccine and meningococcal (Men) B
at 8 weeks, 6-in-1 vaccine (2nd dose), pneumococcal conjugate
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vaccine (PCV) (1st dose) vaccine and rotavirus vaccine (2nd
dose) at 12 weeks, 6-in-1 vaccine (3rd dose) andMenB (2nd dose)
at 16 weeks and Hib/MenC (1st dose), MMR (measles, mumps
and rubella) (1st dose), PCV vaccine (2nd dose) and MenB (3rd
dose) at 52 weeks.
All Ugandan and UK infants were BCG-immunized at birth
or within the first week of life with BCG Danish, Statens Serum
Institut (SSI). Infants in Uganda were randomly assigned in a
1:1 ratio (stratified by maternal LTBI status) to two sampling
strategies to reduce the blood-sampling burden on individual
infants. This resulted in only half the Ugandan infants sampled
at week 10. Peripheral venous blood samples were collected from
infants of mothers with and without LTBI in Uganda at 10 and 52
weeks after BCG immunization. In the UK, maternal LTBI was
not determined prior to collecting a sample from the infants at 10
and 52 weeks. Therefore, all samples were collected regardless of
maternal LTBI status, but only samples from infants of mothers
without LTBI were used for analysis.
Tests for Latent TB Infection
In Uganda, women were examined for LTBI at ∼1 week
post-delivery using the tuberculin skin test (TST) (PPD RT23
SSI, Copenhagen, Denmark) and T-SPOT.TB assay (Oxford
Immunotec, Abingdon, UK). The TST was performed in the
mothers after bleeding for the T-SPOT.TB assay and was read
48–72 h later, and defined as positive if ≥10mm in diameter.
Women positive on both tests were considered LTBI-positive;
those negative on both tests were considered LTBI-negative;
those with indeterminate and inconsistent results were excluded.
LTBI-positive mothers were examined for active tuberculosis by
symptoms, sputum examination (if available), and chest x-ray
and there were no cases of active TB disease detected in mothers
and their infants during the study period, and data available on
the subjects has been reported (17).
In the UK, a 5ml blood sample was obtained from women
at the infant’s 10-week appointment and tested for LTBI using
the T-SPOT.TB assay. If the mother tested positive, infants
were excluded from the study and the clinical team at North
Middlesex Hospital were informed of the result. TST testing was
not available in the UK.
Whole Blood Assays for Cytokine and
Chemokine Responses
Identical standard operating procedures were used in Uganda
and the UK since the assays were performed in the different
laboratories. Reagents from the same manufacturers were used.
Venous blood was diluted 1/5 in RPMI 1640 (Invitrogen)
supplemented with 2mM L-glutamine (Invitrogen) and cultured
at 37◦C in 5% CO2 for 6 days in 96-well U-bottomed
plates. Duplicate wells were incubated with medium alone
(negative control), PPD (Statens Serum Institut, catalog # RT50;
10µg/mL), and with a combination of M. tuberculosis-specific
antigens [6 kDa Early Secreted Antigen ofM. tuberculosis (ESAT-
6) and 10 kDa culture filtrate protein (CFP10)] (BEI Resources,
catalog #s NR14868 and NR-49425; each at 5µg/mL).
After 6 days, plates were centrifuged at 400 g for 5min.
Supernatants were removed from duplicate wells, pooled, and
stored at −80◦C prior to analysis. Thawed supernatants were
randomized across plates and analyzed using the multiplex
bead array using the human cytokine/chemokine MilliplexTM
MAP 17-plex pre-mixed kit (Merck Millipore), following
the manufacturer’s instructions. The pre-mixed bead set
included interleukin (IL)-1α, IL-1β, IL-1Ra, IL-2, IL-5, IL-
8, IL-10, IL-12p40, IL-13, IL-17A, interferon (IFN)-γ, IFN-γ-
inducible protein (IP)-10, monocyte chemotactic protein (MCP)-
1, macrophage inflammatory protein (MIP)-1α, MIP-1β, tumor
necrosis factor (TNF), and granulocyte macrophage colony-
stimulating factor (GM-CSF). Reference samples were included
at both sites to ensure data comparability. Data were acquired
using the Biorad Luminex R© 200 system and Bioplex Manager
Software version 6.1 (Biorad).
Statistical Methods
We conducted analyses to compare immune responses to
mycobacterial antigens in Uganda and UK infants using
blood samples collected at 10 and 52 weeks following BCG
immunization. For the larger study (17), in Uganda, we aimed
to recruit 150 women with LTBI and 150 without, to give 80%
power to detect a difference of 0.35log10 (assuming a standard
deviation of 0.9log10) in infant cytokine response at 52 weeks
between the two groups, and a difference of 0.5log10 at other time
points (with 75 infants in each group). In the UK, we aimed to
recruit a comparison group of 150 women.
The values of cytokine and chemokine response from
unstimulated samples were subtracted from values from antigen-
stimulated samples. Values <3.2 pg/ml were assigned as 3.2
pg/ml. Values above the upper detection limit were assigned
11,000 pg/ml.
Baseline characteristics of participants were summarized by
LTBI exposure status (for infants in Uganda) and by country
using percentages, medians and ranges. Mann Whitney and
chi-squared tests were used to compare baseline characteristics
between Ugandan and UK infants. Cytokine and chemokine
responses were compared by LTBI exposure status, country, and
each time point using the Mann-Whitney U test. Dot plots
were used to visualize distributions of log-transformed cytokine
and chemokine responses at weeks 10 and 52; log-transformed
responses were preferred because they offered clearer visual
comparisons as compared to the raw values. These are presented
as Log10 analyte concentration measured in pg/ml. A significance
level of 0.003 (0.05/17) was used, considering a Bonferroni
correction for multiple comparisons.
Data analysis and presentation were conducted using Stata
15.1 (College Station, Texas, USA) and PRISM v8.11 (224)
(GraphPad software, Inc., La Jolla, CA, USA).
Ethics Approval Statement
Ethics approval was given by the Uganda Virus Research Institute
Research Ethics Committee (reference GC/127/13/09/16 and
GC/127/16/03/434), Uganda National Council for Science and
Technology (reference HS 1526) and London School of Hygiene
& Tropical Medicine (reference 7104 for the Uganda study, 8720-
1 for the UK study) and 15/LO/0048 for the NHS in the UK study.
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All mothers gave written informed consent for their own and
their baby’s participation in the study.
RESULTS
Characteristics of Study Participants
Baseline characteristics of participants are shown in Table 1.
Mothers from the UK were older on average than those from
Uganda (p < 0.001), but median birth weight (p = 0.099)
and sex (p = 0.776) distributions were similar across groups.
Other details about the subjects in this study have been reported
as part of the larger study, including inclusion of those who
were HIV-negative and a lack of difference in the prevalence of
helminth infections between LTBI positive and negative groups
in Uganda (17).
A general comparison of median cytokine responses between
all infants in Uganda and the UK regardless of maternal LTBI
status in Uganda was performed. These responses were further
analyzed to examine the impact of maternal LTBI. Due to loss
of some study subjects to follow up, responses to PPD were
examined at week 10 for 51 infants of mothers with LTBI (UG+)
and 57 infants of mothers without LTBI (UG–) in Uganda and
25 infants in the UK (UK); and at week 52 for 95 infants of
mothers with LTBI (UG+) and 110 infants of mothers without
LTBI (UG–) in Uganda and 12 infants in the UK (UK).
For ESAT6/CFP10, responses were examined at week 10 for
39 infants of mothers with (UG+) and 41 infants of mothers
without LTBI (UG–) in Uganda and 25 infants in the UK (UK);
and at week 52 for 95 infants of mothers with LTBI (UG+) and
109 infants of mothers without LTBI (UG–) in Uganda and 12
infants in the UK (UK).
Immune Response to PPD Stimulation
Cytokine and chemokine responses following stimulation of
infant whole blood with PPD were measured to assess responses
induced by BCG immunization.
At weeks 10 and 52, there were no differences in median
IFN-γ production in response to PPD stimulation of whole
blood between infants in Uganda and the UK (p = 0.2638,
p = 0.8909, respectively). At week 52, median TNF production
was marginally higher in Ugandan infants, but after correction
for multiple testing this was not significant (p= 0.0078, Table 2).
At week 10, the production of three of the 11 cytokines
measured differed significantly between Ugandan and UK infants
following stimulation with PPD (Table 2 and Figure 1). Median
IL-1β responses were significantly higher in Ugandan infants
than in UK infants (p < 0.0001; Table 2 and Figure 1A), whereas
median IL-2 (p = 0.0001) and IL-10 (p < 0.0001) responses
were significantly higher in the UK compared to Ugandan infants
(Table 2 and Figure 1). However, these differences in responses
were not sustained at week 52.
At weeks 10 and 52, the production of IP-10 (p < 0.0001,
p= 0.0001, respectively) in response to PPD stimulation of infant
blood was significantly higher in UK than in Ugandan infants
(Table 2 and Figure 1B). At week 52, production of MIP-1β
was significantly higher in UK infants than in Ugandan infants
(p= 0.0013, Table 2 and Figure 1B).
Immune Response to ESAT6/CFP10
Stimulation
Cytokine and chemokine responses following stimulation of
infant whole blood with a combination of ESAT6 and CFP10
proteins were measured to assess exposure to or infection with
M. tuberculosis or NTM.
At weeks 10 and 52, the production of IFN-γ, TNF, IL-12p40,
IL-1α, IL-1β, IL-1Ra, IP-10, MIP-1α, MIP-1β, and GM-CSF were
significantly higher in Ugandan than in UK infants following
stimulation of blood with ESAT6/CFP10 (Table 3 and Figure 2).
At week 10, blood samples from infants in the UK produced
significantly higher IL-10 (p = 0.0038) and IL-8 (p = 0.0005)
than Ugandan infants (Table 3 and Figure 2B), although these
responses were not sustained at week 52. At week 52, blood
samples from Ugandan infants produced significantly higher
amounts of IL-17A than UK infants (p = 0.0009; Table 3 and
Figure 2A).
Comparison of Responses Based on
Exposure to Maternal LTBI in Ugandan
Infants
We expected that LTBI would be much more common in
Ugandan mothers compared to UK. We compared immune
responses in infants of mothers with and without LTBI in
Uganda with those from UK infants of mothers without LTBI.
As previously reported (17), responses to both PPD and
ESAT6/CFP10 were remarkably similar betweenUgandan infants
of mothers with and without LTBI. However, we expected
responses in infants of Ugandan mothers without LTBI to be
closer to responses from UK infants.
Immune Response to PPD Stimulation
The responses to PPD stimulation of infant blood were generally
similar between infants in Uganda and the UK regardless of
maternal LTBI exposure in Ugandan infants, except for MCP-
1 responses at week 52 where Ugandan infants of mothers
with LTBI had significantly higher responses than UK infants
(p= 0.0024; Figure 1B).
Immune Response to ESAT6/CFP10
Stimulation
At week 10, the production of IL-13 (p= 0.0020, Figure 2A), IL-
10 (p = 0.0022, Figure 2B), and IL-8 (p = 0.0001, Figure 2B)
following stimulation of infant blood with ESAT6/CFP10 was
significantly higher in UK infants than in Ugandan infants
of mothers without LTBI, but comparable to responses from
Ugandan infants of mothers with LTBI. However, these responses
were not sustained at week 52.
DISCUSSION
Based on previous results comparing infants in Malawi and
the UK we had expected differences in immune responses to
BCG immunization between infants in Uganda and the UK.
Immunization of infants in Malawi with BCG has been shown
in previous studies to elicit lower IFN-γ responses to PPD than
Frontiers in Immunology | www.frontiersin.org 4 March 2021 | Volume 12 | Article 637114
Mawa et al. Infant Immune Response to BCG
TABLE 1 | Characteristics of study participants.
UG LTBI– (n = 121) UG LTBI+ (n = 110) UK (n = 25) p-value
Mother’s age (years), median (range) 23 (17–37) 25 (17–42) 34 (19–43) <0.001
Birth weight (kg), median (range) 3.2 (2.5–4.5) 3.2 (2.5–4.4) 3.35 (2.73–4.3) 0.099
Sex of the baby, male n (%) 63 (52%) 64 (58%) 13 (52%) 0.776
P-values are from the Mann Whitney-test for comparisons of mother’s age and birth weight and from the chi-squared-test for comparison of sex proportions between infants from
Uganda (overall) and those from the UK.














IFN-γ 337.5 326.8 0.2638 264.7 265.1 0.8909
TNF 126 59.7 0.2636 69.26 36.04 0.0078
IL-2 5.51 25.5 0.0001 14.86 26.34 0.2908
IL-12p40 2.85 5.97 0.1256 2.395 4.370 0.5677
IL-1α 60.44 94.9 0.4134 10.21 27.25 0.2838
IL-1β 58.96 7.8 <0.0001 22.82 3.535 0.0090
IL-1Ra 180.30 164.6 0.4201 105.9 102.0 0.5018
IL-17A 16.87 22.2 0.1909 14.57 13.37 0.8108
IL-5 36.75 37.2 0.3394 27.92 39.21 0.2417
IL-13 163.8 319.1 0.0595 119.2 138.5 0.3788
IL-10 0.00 7.6 <0.0001 1.64 5.64 0.2087
IL-8 10,159 10605.3 0.0188 10,003 10,609 0.0115
IP-10 10,409 10,877 <0.0001 9,846 10,882 0.0001
MCP-1 4,294 3,525 0.3529 6,133 2,535 0.0104
MIP-1α 230.5 212.4 0.5594 47.49 57.10 0.2915
MIP-1β 268.9 366.6 0.2972 43.85 126.8 0.0013
GM-CSF 413.8 432.9 0.8493 122.5 274.5 0.0306
P-values are from the Mann Whitney-test for comparison of responses between infants from Uganda and those from the UK. Bold-faced values represent statistically significant p-values
at the 0.003 level (Bonferroni corrected).
infants in the UK (11, 23) and, in a more comprehensive analysis
where more cytokines and chemokines were measured, seven
of 42 cytokines and chemokines tested were higher in the UK
infants (Th1 responses) while 20 were higher inMalawian infants
(innate proinflammatory, regulatory, Th2, and Th17 cytokines
and growth factors) at 12 and 52 weeks (13).
We show that infant responses to PPD following BCG
immunization were much more similar between Ugandan and
UK infants than expected, with no suggestion of suppression
of key Th1 responses in Uganda and no Th2 bias as previously
observed in Malawi (13). There were a few differences at week
10 but these were not sustained at week 52 so arguably of no
long-term significance to protective immunity against TB in the
infants. Surprisingly, infants in the UKmounted similar immune
responses to Ugandan infants of mothers with LTBI for some of
the cytokines and chemokines analyzed.
There were important differences between our study and the
Malawi study (13). First, BCG vaccination was administered at
birth or within the first week in our study vs. between 3 and
13 weeks in Lalor’s study. Differences in immune responses
when BCG vaccination is given at birth vs. when delayed
have been previously reported (24, 25). Second, there were
differences in the assays performed: we used 1/5 dilution of
whole blood whereas the Malawi/UK study used 1/10 dilution;
we used 10µg/mL of PPD vs. 5µg/mL in Lalor’s study. Third,
the number of infants analyzed also differed (our Ugandan study
sampled more infants than the Malawian study, but similar
number of infants were sampled in the UK for both studies).
These study-related differences could have contributed to the
observed differences between responses in infants in our study
and those in theMalawi/UK study. In previous studies inMalawi,
infant responses to PPD at early time points were shown to be
influenced by geographic location, season of birth and timing
of vaccination (11, 14). It is possible that infants in Malawi
were vaccinated or blood samples collected after exposure to
environmental mycobacteria that are common in the tropics,
with the consequent low IFN-γ and high immunoregulatory and
Th2 responses observed (26). Factors other than mycobacterial
exposure may also explain the Malawi-UK differences. Of note,
the Malawi study was conducted in a more rural setting than
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FIGURE 1 | Comparison of immune response to PPD in infants from Uganda and United Kingdom. (A) Median IFN-γ, TNF, IL-2, IL-12p40, IL-1α, IL-1β, IL-1Ra,
IL-17A, IL-5, and IL-13 production following 6-day stimulation of whole blood with PPD in infant samples obtained at 10 and 52 weeks after BCG immunization. These
are presented on the log scale in pg/ml. Closed and open circles represent Ugandan infants of mothers with (UG+) and without (UG–) LTBI, respectively. Open
squares represent infants in the UK. The asterisk (*) represents **p < 0.001, ***p < 0.0001. ns, not statistically significant. (B) Median IL-10, IL-8, IP-10, MCP-1,
MIP-1α, MIP-1β and GM-CSF production following 6-day stimulation of whole blood with PPD in infant samples obtained at 10 and 52 weeks after BCG
immunization. These are presented on the log scale in pg/ml. Closed and open circles represent Ugandan infants of mothers with (UG+) and without (UG–) LTBI,
respectively. Open squares represent infants in the UK. The asterisk (*) represents **p < 0.001, ***p < 0.0001. ns, not statistically significant.
the Ugandan study and so factors such as nutrition, helminth
and malaria infections might be different. Also, the adopted EPI
vaccine schedules are different between Uganda, Malawi and
the UK. Other differences between our study and the previous
studies in Malawi, The Gambia, Indonesia and the UK that
could have resulted in the observed differences include the use
of BCG-Danish strain in our study (vs. BCG-Russia in the
study in The Gambia (14) and attenuated live M. bovis strain
Paris in Indonesian study (15). Differences in immune responses
to different strains of BCG vaccine have previously been
reported (27). Previous studies have also attributed differences
in responses to vaccines to the genetic background of the
individuals (28, 29).
EAST6 and CFP10 are considered to be M. tuberculosis-
specific antigens (although some species of NTM express them).
We measured responses to ESAT6 and CFP10 in order to assess
exposure toM. tuberculosis in utero and acquisition of responses
to M. tuberculosis during the first year of life. Responses to
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IFN-γ 20.64 0.000 0.0001 39.49 0.000 <0.0001
TNF 135.2 0.04 <0.0001 313.2 4.395 <0.0001
IL-2 0.000 0.000 0.4912 0.000 0.010 0.1019
IL-12p40 54.14 2.48 <0.0001 37.37 2.87 0.0003
IL-1α 194.2 24.17 <0.0001 107.9 17.74 0.0007
IL-1β 1314 35.57 <0.0001 1,271 65.39 <0.0001
IL-1Ra 134.90 16.03 <0.0001 160.80 11.05 <0.0001
IL-17A 0.000 0.000 0.2819 0.685 0.000 0.0009
IL-5 0.000 0.000 0.5495 0.000 0.000 0.7781
IL-13 0.000 0.000 0.2347 0.000 0.000 0.8188
IL-10 4.200 14.94 0.0038 6.960 9.495 0.1451
IL-8 10,112 10,621 0.0005 10,404 10,740 0.0739
IP-10 1,587 415.7 0.0001 2,064 552.4 0.0009
MCP-1 3,169 3821.8 0.8852 6,117 2,552 0.0509
MIP-1α 2,010 31.86 <0.0001 936.1 35.61 <0.0001
MIP-1β 3,003 176 <0.0001 1472 182.0 0.0012
GM-CSF 21.59 1.41 <0.0001 17.78 0.605 0.0005
P-values are from the Mann Whitney-test for comparison of responses between infants from Uganda and those from the UK. Bold-faced values represent statistically significant p-values
at the 0.003 level (Bonferroni corrected).
ESAT6/CFP10 were generally higher in Ugandan infants for
most cytokines and chemokines measured, at both week 10 and
52, indicating a much greater exposure to M. tuberculosis (or
possibly to ESAT6/CFP10-containing NTM) in Uganda than
the UK (26). Moreover, the IFN-γ and TNF responses to
ESAT6/CFP10 in infants in Uganda increased with age (17),
which would also support progressive exposure over time to or
infection with M. tuberculosis or NTM. The concentrations of
other cytokines and chemokines in response to ESAT6/CFP10
stimulation were overall higher in Ugandan infants than in the
UK. The ESAT6/CFP10-expressing NTM such as M. szulgai
(30) have previously been identified in Ugandan infants and
adolescents where the overall prevalence of NTM in infants
from rural Uganda investigated for pulmonary tuberculosis was
3.7% (31).
We were interested in whether the differences observed for
overall median responses to mycobacterial antigens between
Ugandan and UK infants were influenced by maternal LTBI
exposure of Ugandan infants, though we recently demonstrated
that, in Uganda, maternal LTBI does not influence infant
responses to BCG immunization (17). Similarly, in this analysis
we did not find differences in the immune response between
infants of mothers with and without a LTBI for most cytokines
except for IL-10, IL-13, and IL-8 responses to ESAT6/CFP10
stimulation that were higher in UK infants than in Ugandan
infants of mothers without LTBI, at 10 weeks. This is a
surprising, but interesting result since we expected the infants
in the UK and Ugandan infants of mothers without LTBI to
mount relatively similar immune responses. However, these
responses were not sustained at 52 weeks and therefore may
not have long-term significance for protective immunity against
TB in the infants. Although statistically significant differences
were obtained between the infants of Ugandan mothers with
or without LTBI for these cytokines, the values were either
very low (IL-13) or very high (IL-8). Thus, differences in
cytokines with concentrations in the mid-range such as IL-
10 may be more meaningful. IL-8 plays an important role
during granuloma formation and is involved in recruiting
neutrophils, T cells and monocytes to the site of infection (32,
33). Production of IL-8 by neonatal T cells has also recently
been demonstrated as an anti-microbial effector mechanism (34).
Th2 immunity, characterized by IL-4 and IL-13, is thought to
antagonize protective Th1 responses to TB (35). Th2 activation
of macrophages results in alternatively activated phenotypes
that are less potent in their antimicrobial activity (36). IL-
10 is an immunomodulatory cytokine with a potential effect
on many cells, including macrophages (37). IL-10 has been
shown to regulate phagosome maturation during human M.
tuberculosis infection thus highlighting its potential role in
sustaining pathogen persistence (38). Collectively, the fact that
these cytokines were present in greater concentrations in the
UK infants (although with the caveats regarding concentrations
discussed above) could imply either beneficial or detrimental
effects on anti-mycobacterial immunity.
Contrary to the above observations, median MCP-
1 response to PPD stimulation was significantly higher
in Ugandan infants of mothers with LTBI than in UK
infants, at week 52. MCP-1 is thought to contribute to the
inflammatory responses driven by T lymphocytes (39, 40).
This may partly explain the lack of differences in the Th1 or
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FIGURE 2 | Comparison of immune response to ESAT6/CFP10 in infants from Uganda and United Kingdom. (A) Median IFN-γ, TNF, IL-2, IL-12p40, IL-1α, IL-1β,
IL-1Ra, IL-17A, IL-5, and IL-13 production following 6-day stimulation of whole blood with ESAT6/CFP10 in infant samples obtained at 10 and 52 weeks after BCG
immunization. These are presented on the log scale in pg/ml. Closed and open circles represent Ugandan infants of mothers with (UG+) and without (UG–) LTBI,
respectively. Open squares represent infants in the UK. The asterisk (*) represents **p < 0.001, ***p < 0.0001. ns, not statistically significant. (B) Median IL-10, IL-8,
IP-10, MCP-1, MIP-1α, MIP-1β, and GM-CSF production following 6-day stimulation of whole blood with ESAT6/CFP10 in infant samples obtained at 10 and 52
weeks after BCG immunization. These are presented on the log scale in pg/ml. Closed and open circles represent Ugandan infants of mothers with (UG+) and without
(UG–) LTBI, respectively. Open squares represent infants in the UK. The asterisk (*) represents **p < 0.001, ***p < 0.0001. ns, not statistically significant.
proinflammatory responses observed between infants in Uganda
and the UK.
Additional assays such as intracellular cytokine staining and
flow cytometry would be needed to identify the cellular sources
of these cytokines and chemokines. We chose the Luminex assay
instead as our primary read out, so that we could assess a range
of cytokine/chemokine responses. Moreover, cell phenotype and
function following BCG immunization of infants have previously
been assessed by our team and others (9, 41–43).
The finding that there is no difference in Th1 responses to PPD
between infants in Uganda and the UK calls for a re-evaluation
of our understanding of the variability in protection afforded
by BCG. In the UK, only infants of mothers without LTBI
were included. The remarkable similarity in IFN-γ responses to
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PPD between Ugandan and UK infants post-BCG may suggest
that the stimulus of BCG was able to override effects of prior
(prenatal), or even concurrent, mycobacterial exposures (or lack
of them).
Previous studies in Uganda and the UK assessed innate
immune responses in cord blood and in BCG vaccinated
infants, measuring cytokine responses after 24 h of stimulation
(16, 44), although the design of the Ugandan study did not
allow assessment of post-vaccination immune responses. Our
recent longitudinal study (17) showed very high proportions
of infants who produced high cord blood cytokine levels in
response to stimulation with mycobacterial antigens, regardless
of mother’s TB exposure status. However, there was no evidence
of differences in the subsequent evolution of responses to PPD
based on cord blood cytokine profiles. In the present study a
longer 6-day culture period was used to enable restimulation
of antigen-specific memory T cell responses, so although we
cannot rule out that these may have been influenced by earlier
release of innate cytokines, or that some cytokines derived
from innate immune cells might still be present [as a result
of influence of innate immunity on adaptive immunity (45)
and BCG-induced increases in function of innate cells (46,
47)], we predict that most of the cytokines are derived from
T cells.
One limitation of recruiting volunteers in the UK was that
the study period overlapped with a global BCG shortage that
also affected the UK (48), thus restricting the number of BCG
vaccinated infants that could be recruited within the study
period. Moreover, the smaller than planned sample size did
not impact the findings, since we see differences for ESAT6
alongside no differences for PPD. Another limitation of the
study is the small amount of blood available from infants
and this limited the number of assays possible. This is a
common occurrence with exploratory immunological studies.
Moreover, we used an assay (Luminex) that enabled us to assess
a range of cytokines/chemokines using the available amount
of sample (which was sufficient for this purpose). We were
therefore able to address the objectives of the study. In the
UK, by study design, infant samples were only collected at
weeks 10 and 52 and from infants of mothers without LTBI.
Thus, we did not have pre-vaccination or cord blood samples
collected from UK infants for a pre-vaccination comparison
with the infants in Uganda. As TB incidence is relatively low
in the UK, recruitment of mothers with LTBI would require
a targeted recruitment drive (for example, identifying contacts
of TB cases) which this study was not designed to do. Also,
we did not adjust for confounders since the data available was
quite minimal.
In conclusion, immune responses to mycobacterial antigens
following BCG immunization are similar for PPD, but
differ for ESAT6/CFP10, between infants in Uganda and
the UK. We show that neither maternal LTBI nor infant
exposure to or infection with M. tuberculosis (or NTM)
impacts response to PPD following BCG immunization.
The observed differences in immune response to, and
efficacy of, BCG immunization are likely to be due to
other causes.
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